Details for New Drug Application (NDA): 020863
✉ Email this page to a colleague
The generic ingredient in PLETAL is cilostazol. There are twelve drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the cilostazol profile page.
Summary for 020863
Tradename: | PLETAL |
Applicant: | Otsuka |
Ingredient: | cilostazol |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Jan 15, 1999 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Jan 15, 1999 | TE: | RLD: | Yes |
Expired US Patents for NDA 020863
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Otsuka | PLETAL | cilostazol | TABLET;ORAL | 020863-001 | Jan 15, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Otsuka | PLETAL | cilostazol | TABLET;ORAL | 020863-002 | Jan 15, 1999 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription